Prednisone

General description

INN	Prednisone
Medicine type	Chemical agent
EML status history	First added in 2021 (TRS 1035) for Allergic or hypersensitivity conditions of unspecified type Changed in 2021 (TRS 1035) for Follicular lymphoma Changed in 2021 (TRS 1035) for Chronic lymphocytic leukaemia or small lymphocytic lymphoma Changed in 2021 (TRS 1035) for Plasma cell myeloma Changed in 2021 (TRS 1035) for Malignant neoplasms of prostate Changed in 2021 (TRS 1035) for Lymphoid leukaemia, not elsewhere classified Changed in 2021 (TRS 1035) for Diffuse large B-cell lymphoma, not otherwise specified Changed in 2021 (TRS 1035) for Hodgkin lymphoma Changed in 2023 (TRS 1049) for Langerhans cell histiocytosis Changed in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-positive Changed in 2023 (TRS 1049) for Anaplastic large cell lymphoma, ALK-negative Changed in 2025 (TRS 1064) for Adrenocortical insufficiency
Therapeutic equivalent for	prednisolone for Allergic or hypersensitivity conditions of unspecified type prednisolone for Follicular lymphoma, unspecified prednisolone for Lymphoid leukaemia, not elsewhere classified prednisolone for Chronic lymphocytic leukaemia or small lymphocytic lymphoma prednisolone for Diffuse large B-cell lymphoma, not otherwise specified prednisolone for Hodgkin lymphoma, unspecified prednisolone for Anaplastic large cell lymphoma, ALK-negative prednisolone for Plasma cell myeloma prednisolone for Malignant neoplasms of prostate, unspecified prednisolone for Langerhans cell histiocytosis prednisolone for Anaplastic large cell lymphoma, ALK-positive prednisolone for Adrenocortical insufficiency
Wikipedia	Prednisone
DrugBank	Prednisone